Congress and CMS Advance AI and Value-Based Care in U.S. Healthcare
What happened
Congress introduced bipartisan legislation requiring human review of AI-driven medical decisions. Separately, the Centers for Medicare & Medicaid Services expanded its value-based ACCESS model to cover additional chronic conditions and unveiled plans for an AI-inferred risk-adjustment model in its LEAD ACO program. The FDA and CMS are co-acting to shape the regulatory landscape for artificial intelligence in healthcare.
From mondaq.com
Why it matters
These regulatory actions accelerate the federal framework for artificial intelligence in healthcare. The expansion of CMS's value-based model directly impacts how healthcare providers are reimbursed for managing chronic conditions.
From mondaq.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
Keep exploring
The entities involved
-
Congress
US record label; imprint of Congress Record Corp.
-
CMS
International law firm
- FDA
-
Federal Trade Commission
United States federal government agency
Related events
- The FDA and Department of Health & Human Services are currently collaborating to regulate and shape the use of artificial intelligence in healthcare.
- CMS rules are impacting American healthcare costs, and Congress is involved in building on these rules for transparency.
- The Federal Trade Commission is investigating the safety risks associated with AI systems.
- Dario Amodei warns government leaders about AI risks and calls for strict guardrails on AI development.
- CSPI is campaigning for stronger federal and state food safety policies and collaborating with the CDC on regulatory campaigns.